Physicians' Academy for Cardiovascular Education

Stroke

Low LDL-c and TG levels associated with risk of hemorrhagic stroke in women

Literature - Apr. 18, 2019 - Rist PM et al., - Neurology 2019

In a large, prospective cohort of women, those with LDL-c <70 mg/dL and potentially those with LDL-c ≥160 mg/dL and those with low TG, showed a higher risk of hemorrhagic stroke.

Higher consumption of dietary cholesterol or eggs linked to increased risk of incident CVD and mortality

Literature - Apr. 4, 2019 - Zhong VW et al. - JAMA 2019
Among US adults, higher consumption of dietary cholesterol or eggs was significantly associated with higher risk of incident CVD and all-cause mortality in a dose-response manner.

Among US adults, higher consumption of dietary cholesterol or eggs was significantly associated with higher risk of incident CVD and all-cause mortality in a dose-response manner.

No reduction in mortality and CV outcomes with catheter ablation in AF

Literature - Apr. 2, 2019 - Packer DL, et al. - JAMA 2019

In the CABANA trial, catheter ablation did not result in a reduction of death, disabling stroke, serious bleeding or cardiac arrest in symptomatic AF patients compared to drug therapy.

DOACs may reduce thromboembolic events in patients with mitral stenosis and AF

Literature - Mar. 13, 2019 - Kim JY et al. - JACC 2019

In an exploratory analysis of insurance data, DOAC use reduced stroke or systemic embolism in patients with mitral stenosis and AF compared to warfarin.

Better clinical outcomes with DOACs vs. warfarin in patients with NVAF and low body weight

Literature - Mar. 5, 2019 - Lee S-R et al. - JACC 2019
An Asian cohort of adults with non-valvular AF and low or very low body weight (<60/50 kg), showed better effectiveness and safety with regular and reduced DOAC dose, compared with warfarin.

An Asian cohort of adults with non-valvular AF and low or very low body weight (<60/50 kg), showed better effectiveness and safety with regular and reduced DOAC dose, compared with warfarin.

Diet drinks associated with increased risk of CV outcomes and all-cause mortality in postmenopausal women

Literature - Feb. 25, 2019 - Mossavar-Rahmani Y et al. - Stroke 2019

Self-reported consumption of ≥2 artificially sweetened beverages per day was associated with higher risk of CV events, and all-cause mortality in postmenopausal women, as shown in an observational study.

Large meta-analysis confirms efficacy of statins in primary CVD prevention, but individual benefit-harm profiles vary

Literature - Feb. 18, 2019 - Yebyo HG et al. - Am Heart J 2019

This meta-analysis of RCTs on statins demonstrated reduced risk of most CVD outcomes in primary prevention populations, with increased risk of some side effects. A network meta-analysis revealed different benefit-harm profiles for specific statins.

Treatment with GLP-1RA results in reduction of MACE in type 2 diabetes patients with established CVD

Literature - Feb. 12, 2019 - Hernandez AF et al. - The Lancet 2018

Albiglutide was superior to placebo with respect to MACE in T2DM patients in the Harmony Outcomes trial without differences in serious adverse events.

AF patients with cognitive impairment or frailty less likely to receive OAC

Literature - Feb. 12, 2019 - Madhavan M et al. - Am Heart J 2019

In the ORBIT-AF multicenter cohort study, AF patients with cognitive impairment or frailty showed higher stroke risk and mortality, but OACs were underprescribed. The conditions did not affect OAC treatment effect.

Large reduction of major vascular events with statins in older individuals

Literature - Feb. 11, 2019 - Cholesterol Treatment Trialists’ Collaboration - The Lancet 2019

A meta-analysis of 28 large RCTs including more than 14.000 individuals aged >75 years showed that the use of statins resulted in significant reductions of major vascular events regardless of age.

Combination of DOAC with aspirin effective for prevention of stroke in patients with CAD or PAD

Literature - Feb. 5, 2019 - Sharma M et al. - Circulation 2019

Low-dose rivaroxaban plus aspirin reduced the risk for stroke in patients with CAD or PAD, especially in those with prior stroke, as shown in a subanalysis of the COMPASS trial.

Reduced CV events with loading dose of statin before PCI in patients with ACS

Literature - Jan. 28, 2019 - Ye Z et al. - Eur Heart J 2019

A meta-analysis of 13 randomized controlled trials showed that a loading dose of atorvastatin before PCI markedly reduced MACE in patients with ACS.